We are sort of hanging out at these levels. Perhaps we have a modest little downtrend but I sort of see the sector more in a holding pattern more than anything else. I know we are waiting for inflation and rates to move down and our expectations are that it helps the sector. What if […]
May 31st Biotech Update
Nothing really to add on the sector or market in general. It is all about inflation and rates and will be so for the foreseeable future. The sector has been struggling a little and I think probably a little more than I would have originally expected. I understand that rates are heading up a little […]
May 29th Biotech Update
There is not a lot to say about the broader sector or even the broader market. It seems like anyone who wants to go long is buying NVDA and semis and every other sector is being impacted by the higher rates. I am not convinced that the move higher in rates is sustainable as I […]
May 28th Biotech Update
There was not a lot of interest in the sector in front of a long weekend. That is somewhat interesting as usually a long weekend sparks dreams of potential deals being finished. While M&A has been fine this year, there does not seem to be the level of excitement or interest that we have seen […]
Mailing List
Introduction
Overview
Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.
